8th Complement-based Drug Development Summit
Boston, Massachusetts, United States
Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors
The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.
With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question: which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?
From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.
Date and Time: Tuesday, 10 December 2024 at 09:00 to Thursday, 12 December 2024 at 18:00